At a glance
- Note: These files are not yet fully accessible for all audiences.
- Slides will be added as they become available.
September 18, 2025
Welcome and Roll Call
Dr. Martin Kulldorff
Dr. Mina Zadeh
Update on Work Groups
Dr. M Kulldorff
Measles, Mumps, Rubella, and Varicella (MMRV) Vaccines
*Background briefing material* Rapid systematic review of the safety of MMRV vaccine
*Background briefing document* Policy recommendations for the use of MMRV vaccines in the U.S.
Introduction
Dr. M Kulldorff
Dr. A Srinivasan
Febrile seizures following measles, mumps, rubella, and varicella (MMRV) vaccine
Dr. J Su
Proposed recommendations and discussion
Dr. M Kulldorff
Hepatitis B Vaccine
*Background briefing document* Hepatitis B birth dose briefing document
*Background briefing material* The non-specific effects of hepatitis B vaccines
Introduction
Dr. M Kulldorff
Presentation on hepatitis B birth dose vaccination
Dr. A Langer
A review of the safety of hepatitis B birth dose vaccination
Dr. J Su
Non-specific effects following hepatitis B vaccination
Dr. J Su
Proposed recommendations and discussion
Dr. M Kulldorff
September 19, 2025
Welcome and Roll Call
Dr. Martin Kulldorff
Dr. Mina Zadeh
COVID-19 Vaccines
Introduction
Dr. R Levi
Dr. A Srinivasan
Updates to 2024-2025 COVID-19 Implementation Considerations
Dr. A Srinivasan
COVID-19 vaccine effectiveness update
Dr. A Srinivasan
Vaccine safety signal detection and evaluation
Dr. J Su
Workgroup safety uncertainties of mRNA COVID vaccines
Dr. W El-Deiry & Dr. C Kuperwasser
Genomics of vaccine-induced myocarditis
Dr. B Carleton
Economic analysis of COVID-19 vaccination
Dr. A Srinivasan on behalf of the University of Michigan
COVID-19 Vaccine Manufacturer updates
TBD
COVID-19 Discussion Framing
Dr. R Levi
Proposed recommendations and discussion
Dr. R Levi